mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation

Víctor H. Villar(Université de Bordeaux), Tra Ly Nguyen(Université de Bordeaux), Vanessa Delcroix(Inserm), Silvia Terés(Université de Bordeaux), Marion Bouchecareilh(Centre National de la Recherche Scientifique), Bénédicte Salin(Centre National de la Recherche Scientifique), Clément Bodineau(Université de Bordeaux), Pierre Vacher(Inserm), Muriel Priault(Centre National de la Recherche Scientifique), Pierre Soubeyran(Inserm), Raúl V. Durán(Université de Bordeaux)
Nature Communications
January 23, 2017
Cited by 89Open Access
Full Text

Abstract

A master coordinator of cell growth, mTORC1 is activated by different metabolic inputs, particularly the metabolism of glutamine (glutaminolysis), to control a vast range of cellular processes, including autophagy. As a well-recognized tumour promoter, inhibitors of mTORC1 such as rapamycin have been approved as anti-cancer agents, but their overall outcome in patients is rather poor. Here we show that mTORC1 also presents tumour suppressor features in conditions of nutrient restrictions. Thus, the activation of mTORC1 by glutaminolysis during nutritional imbalance inhibits autophagy and induces apoptosis in cancer cells. Importantly, rapamycin treatment reactivates autophagy and prevents the mTORC1-mediated apoptosis. We also observe that the ability of mTORC1 to activate apoptosis is mediated by the adaptor protein p62. Thus, the mTORC1-mediated upregulation of p62 during nutrient imbalance induces the binding of p62 to caspase 8 and the subsequent activation of the caspase pathway. Our data highlight the role of autophagy as a survival mechanism upon rapamycin treatment.


Related Papers

No related papers found

Powered by citation graph analysis